Protocol Ledger

NCT05461339 · Phase III · ACTIVE NOT RECRUITING

TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration

Interventional Phase III clinical trial protocol NCT05461339 sponsored by BioDlink Biopharm Co in Ophthalmology and Sensory, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-06-28 Enrollment: 488 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05461339
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)488 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05461339
Protocol FieldVerified Registry Value
NCT IdentifierNCT05461339
Consolidated Lead SponsorBioDlink Biopharm Co
Therapeutic Condition CohortOphthalmology and Sensory
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment488 participants (ESTIMATED)
Registered Start Date2022-06-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Ophthalmology and Sensory Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI